Discontinued — last reported Q3 '18
West Pharmaceutical Services Derivative Assets - Not Designated as Hedging Instruments decreased by 36.8% to $4.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 63.6%, from $13.20M to $4.80M. Over 5 years (FY 2020 to FY 2025), Derivative Assets - Not Designated as Hedging Instruments shows an upward trend with a 20.4% CAGR.
derivative_assets_non_hedging| Q4 '21 | Q1 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.80M | $23.30M | $4.50M | $3.50M | $2.20M | $10.30M | $14.70M | $9.90M | $18.30M | $13.20M | $47.00M | $27.00M | $7.60M | $4.80M |
| QoQ Change | — | +57.4% | -80.7% | -22.2% | -37.1% | +368.2% | +42.7% | -32.7% | +84.8% | -27.9% | +256.1% | -42.6% | -71.9% | -36.8% |
| YoY Change | — | — | -69.6% | -85.0% | -51.1% | +194.3% | — | — | +731.8% | +28.2% | +219.7% | +172.7% | -58.5% | -63.6% |